AAM
CRSP icon

Advisors Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Advisors Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$263K Sell
5,519
-186
-3% -$9.81K ﹤0.01% 1100
2025
Q4 		$299K Buy
5,705
+1,051
+23% +$62.9K 0.01% 1070
2025
Q3 		$302K Sell
4,654
-585
-11% -$33.6K 0.01% 1060
2025
Q2 		$255K Sell
5,239
-1,646
-24% -$63.7K ﹤0.01% 1079
2025
Q1 		$234K Sell
6,885
-839
-11% -$35.6K ﹤0.01% 1080
2024
Q4 		$304K Sell
7,724
-1,945
-20% -$91.8K 0.01% 1039
2024
Q3 		$454K Buy
9,669
+342
+4% +$17.4K 0.01% 961
2024
Q2 		$504K Sell
9,327
-135
-1% -$7.81K 0.01% 900
2024
Q1 		$645K Buy
9,462
+2,814
+42% +$201K 0.01% 842
2023
Q4 		$416K Sell
6,648
-570
-8% -$31.5K 0.01% 948
2023
Q3 		$328K Buy
7,218
+1,507
+26% +$77.8K 0.01% 1013
2023
Q2 		$321K Sell
5,711
-6,094
-52% -$346K 0.01% 1034
2023
Q1 		$534K Sell
11,805
-100
-0.8% -$4.86K 0.01% 917
2022
Q4 		$484K Sell
11,905
-10,509
-47% -$557K 0.01% 932
2022
Q3 		$1.47M Sell
22,414
-1,481
-6% -$107K 0.03% 589
2022
Q2 		$1.45M Sell
23,895
-3,775
-14% -$222K 0.03% 624
2022
Q1 		$1.74M Sell
27,670
-9,307
-25% -$584K 0.03% 630
2021
Q4 		$2.8M Sell
36,977
-817
-2% -$71.4K 0.04% 489
2021
Q3 		$4.23M Buy
37,794
+3,702
+11% +$465K 0.06% 314
2021
Q2 		$5.52M Buy
34,092
+5,284
+18% +$643K 0.08% 243
2021
Q1 		$3.51M Buy
28,808
+12,024
+72% +$1.82M 0.05% 369
2020
Q4 		$2.57M Buy
16,784
+13,251
+375% +$1.57M 0.04% 437
2020
Q3 		$296K Buy
3,533
+1,636
+86% +$145K 0.01% 1071
2020
Q2 		$139K Buy
+1,897
New +$111K ﹤0.01% 1246

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Advisors Asset Management's CRSP Position: Q1 2026 in Review

Advisors Asset Management reduced its CRISPR Therapeutics (CRSP) stake by 3.3% in Q1 2026, selling an estimated $9.81K and leaving 5,519 shares worth $263K. The position accounts for ﹤0.01% of the portfolio, ranked #1100.

Advisors Asset Management first reported a position in CRSP in Q2 2020 and has held it in 24 quarters since. The position peaked at $5.52M in Q2 2021. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Advisors Asset Management held 5,519 shares of CRISPR Therapeutics worth $263K as of Q1 2026.
  • Advisors Asset Management sold 186 CRISPR Therapeutics shares in Q1 2026, an estimated $9.81K.
  • CRISPR Therapeutics made up ﹤0.01% of Advisors Asset Management's portfolio in Q1 2026, its #1100 holding.
  • Advisors Asset Management first reported a position in CRISPR Therapeutics in Q2 2020 and has held it in 24 quarters since.
  • Advisors Asset Management's CRISPR Therapeutics position peaked at $5.52M in Q2 2021.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Advisors Asset Management's 13F filing for Q1 2026, filed 15 May 2026.